Foot and Mouth Disease Virus and Novel Vaccines Developments
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 56570
Special Issue Editor
Interests: pathogenic determinants of foot and mouth disease virus; virus–host interaction; safer foot and mouth disease virus vaccines
Special Issue Information
Dear Colleagues,
Foot-and-mouth disease (FMD) is a contagious vesicular disease caused by a highly variable RNA virus (FMDV) affecting cloven-hoofed animals with severe social and economic consequences worldwide. Chemically inactivated whole virus vaccines have been used to contain the disease, but are slow acting and do not always permit distinction between infected and vaccinated animals. New rapid vaccines and emergency response measures, such as therapeutics, need to be developed to allow for rapid containment of future FMDV outbreaks in addition to methods that distinguish between infected and vaccinated animals.
This Special Issue will cover FMDV determinant of replication and pathogenesis and how this information has facilitated next-generation FMDV vaccine and biotherapeutic developments. We particularly encourage the submission of manuscripts focused on improved control strategies addressing important gaps of the current inactivated FMDV vaccine including, but not limited to, duration of immunity, crossreactivity, correlates of protection, early protection, antigen load, immunization responses, and safer marker vaccines.
Dr. Elizabeth Rieder
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- foot-and-mouth-disease virus
- next-generation FMDV vaccines
- vaccine
- biotherapeutics
- correlates of protection
- infection and immunity
- humoral immunity
- cellular immunity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.